CO6361948A2 - Uso de antigeno de mycoplasma bovis - Google Patents

Uso de antigeno de mycoplasma bovis

Info

Publication number
CO6361948A2
CO6361948A2 CO11058044A CO11058044A CO6361948A2 CO 6361948 A2 CO6361948 A2 CO 6361948A2 CO 11058044 A CO11058044 A CO 11058044A CO 11058044 A CO11058044 A CO 11058044A CO 6361948 A2 CO6361948 A2 CO 6361948A2
Authority
CO
Colombia
Prior art keywords
additional
bovis
cattle
infections
prophylaxis
Prior art date
Application number
CO11058044A
Other languages
English (en)
Inventor
Michael Beck
Phillip Wayne Hayes
Jeffrey P Knittel
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of CO6361948A2 publication Critical patent/CO6361948A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Abstract

La presente invención se refiere a vacunas de combinación y/o al uso combinado de composiciones inmunógenas para el tratamiento y/o profilaxis de ganado contra infecciones microbianas, donde las infecciones están causadas por M. bovis y al menos un patógeno relevante de ganado adicional. La vacuna de combinación, como se describe en la presente memoria, comprende al menos un antígeno de M. bovis, preferiblemente el M. bovis atenuado avirulento que se proporciona con la presente memoria y uno o más componentes inmunológicamente activos adicionales eficaces para el tratamiento y/o la profilaxis de infecciones causadas por un patógeno adicional de ganado adicional.
CO11058044A 2008-10-31 2011-05-11 Uso de antigeno de mycoplasma bovis CO6361948A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11028608P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
CO6361948A2 true CO6361948A2 (es) 2012-01-20

Family

ID=41435150

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11058044A CO6361948A2 (es) 2008-10-31 2011-05-11 Uso de antigeno de mycoplasma bovis

Country Status (15)

Country Link
US (1) US8815255B2 (es)
EP (1) EP2362780B1 (es)
JP (1) JP2012507537A (es)
KR (1) KR20110089260A (es)
CN (1) CN102202685A (es)
AR (1) AR074083A1 (es)
AU (1) AU2009309041B2 (es)
CA (1) CA2740954C (es)
CL (1) CL2011000877A1 (es)
CO (1) CO6361948A2 (es)
MX (1) MX2011004316A (es)
NZ (1) NZ591950A (es)
SG (1) SG10201506597RA (es)
UY (1) UY32208A (es)
WO (1) WO2010051210A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121721A4 (en) * 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
AR069087A1 (es) * 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
CA2740954C (en) 2008-10-31 2018-09-25 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
TR201906323T4 (tr) * 2010-12-22 2019-05-21 Bayer Ip Gmbh Sığır türlerinde artırılmış bağışıklık yanıtı.
US9175049B2 (en) 2012-10-24 2015-11-03 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant mycobacterium avium subsp. paratuberculosis proteins induce immunity and protect against infection
PL2938747T3 (pl) 2012-12-28 2019-11-29 Boehringer Ingelheim Vetmedica Gmbh Sposób wytwarzania szczepionki przeciwko mykoplazmie
AU2015222102B2 (en) 2014-02-28 2021-08-19 Bayer Animal Health Gmbh Immunostimulatory plasmids
BR112018002919B1 (pt) * 2015-08-14 2024-02-27 Zoetis Services Llc Composição imunogênica eficaz compreendendo uma cepa de mycoplasma bovis e usos da mesma para prevenção de doenças causadas por mycoplasma bovis
RU2707289C1 (ru) * 2018-06-07 2019-11-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Кубанский государственный аграрный университет имени И.Т. Трубилина" Способ изготовления вакцины, ассоциированной против эшерихиоза, стрептококкоза и псевдомоноза крупного рогатого скота
CN111733094B (zh) * 2020-05-29 2022-09-09 内蒙古民族大学 一种牛源蜡样芽孢杆菌及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8296498A (en) 1997-07-10 1999-02-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of attenuating pathogenic mycobacteria and strains of mycobacteria so attenuated
EP0965639A1 (en) 1998-06-05 1999-12-22 Boehringer Ingelheim Vetmedica Gmbh Attenuated pestiviruses
IL149471A0 (en) 1999-11-08 2002-11-10 Biomune Vaccines for mycoplasma bovis and methods for immunizing bovine amimals
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
US20030147914A1 (en) * 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
JP2004537543A (ja) 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法
RU2004105962A (ru) 2001-08-28 2005-03-27 Пфайзер Продактс Инк. (Us) Модель инфицирования mycoplasma bovis, способы введения m. bovis и способы индуцирования пневмонических повреждений легких
DE102004025452A1 (de) 2004-05-19 2006-01-19 Boehringer Ingelheim Vetmedica Gmbh Vakzine enthaltend BVDV
US20070009545A1 (en) 2005-07-07 2007-01-11 Joachim Frey Mycoplasma subunit vaccine
EP2121721A4 (en) 2006-09-07 2010-10-06 Boehringer Ingelheim Vetmed GENOTYPING BASED ON PCR
US20090068231A1 (en) 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
AR069087A1 (es) 2007-10-29 2009-12-30 Boehringer Ingelheim Vetmed Cepa bacteriana de m. bovis atenuada avirulenta obtenida por pases, vacuna de micoplasma boris y metodos de uso de la misma
CA2729080C (en) 2008-07-03 2018-09-11 Ricardo Rosenbusch Cattle vaccines
CA2740954C (en) 2008-10-31 2018-09-25 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine composition
UY32570A (es) 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada

Also Published As

Publication number Publication date
CN102202685A (zh) 2011-09-28
KR20110089260A (ko) 2011-08-05
EP2362780B1 (en) 2019-12-25
SG10201506597RA (en) 2015-10-29
CL2011000877A1 (es) 2011-09-16
US8815255B2 (en) 2014-08-26
AU2009309041A1 (en) 2010-05-06
MX2011004316A (es) 2011-06-16
UY32208A (es) 2010-05-31
AR074083A1 (es) 2010-12-22
US20120093854A1 (en) 2012-04-19
JP2012507537A (ja) 2012-03-29
CA2740954A1 (en) 2010-05-06
WO2010051210A1 (en) 2010-05-06
EP2362780A1 (en) 2011-09-07
AU2009309041B2 (en) 2016-02-04
CA2740954C (en) 2018-09-25
NZ591950A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
UY29915A1 (es) Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
CL2016000650A1 (es) Composicion de vacuna que comprende un antigeno y una formulacion coadyuvante, que comprende al menos el 50 % v/v de una fase oleosa, monofosforil-lipido a (mpl-a) o un analogo del mismo y un oligonucleotido inmunoestimulate; y uso de la composición de vacuna para preparar un medicamento.
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
CO6511229A2 (es) Metodos para reducir la actividad viricida en composiciones pcv-2 y composiciones pcv-2 con una inmunogeicidad mejorada
PE20151588A1 (es) Vacuna contra el virus del dengue
AR065319A1 (es) Prevencion y tratamiento de pcvd subclinica
UY31437A1 (es) Vacuna de mycoplasma bovis y métodos de uso de la misma
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CO6751260A2 (es) Vacunas basadas en omv contra infecciones por burkholderia
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
MY191905A (en) M hyo multivalent vaccine and uses thereof
MX370584B (es) Vacuna contra lawsonia intracellularis y circovirus porcino 2.
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания
BR112012014689A2 (pt) composição de vacina
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112013023354A2 (pt) vacina para rinite equina
BR112016009076A2 (pt) Composição, processos para preparar um compósito de fluoreto de cálcio e uma composição imunogênica, e, métodos para tratamento ou prevenção de uma infecção ou uma doença causada por vírus, bactéria ou parasita e para induzir uma resposta imunogênica em um humano
CL2022000086A1 (es) Vacunas contra ehrlichia y composiciones inmunogénicas
MX2019013779A (es) Vacuna que comprende toxoides de clostridium.
BR112018069193A2 (pt) uma vacina de combinação contra infecção por vírus pcv2 e prrs compreendendo albumina

Legal Events

Date Code Title Description
FG Application granted